Insmed reported $674.73M in Current Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
DBV Technologies DBVT:US 259.95M 169.52M
Acelrx Pharmaceuticals ACRX:US $ 42.81M 12.68M
Alimera Sciences ALIM:US $ 33.07M 1.68M
Biomarin Pharmaceutical BMRN:US $ 2517.6M 123.57M
Cytokinetics CYTK:US $ 602.25M 21.28M
Dynavax Technologies DVAX:US $ 955.4M 14.89M
Gilead Sciences GILD:US $ 13705M 1076M
Heron Therapeutics HRTX:US $ 194.21M 28.38M
Insmed INSM:US $ 674.73M 81.41M
Mirati Therapeutics MRTX:US $ 1202.93M 140.19M
Novartis NVS:US $ 38142M 906M
Ophthotech OPHT:US $ 317.22M 33.74M
Regeneron Pharmaceuticals REGN:US $ 15529.9M 1223.9M
Sarepta Therapeutics SRPT:US $ 2469.3M 61.65M
Seattle Genetics SGEN:US $ 2778.66M 7.4M
Ultragenyx Pharmaceutical RARE:US $ 678.54M 28.98M
Vertex Pharmaceuticals VRTX:US $ 11503.5M 1142.2M